Monopar Therapeutics (MNPR) Corporate presentation summary

Company overview and leadership

• Clinical-stage biopharmaceutical firm focused on ALXN1840 for Wilson disease and MNPR-101 for oncology.

• ALXN1840 is an oral, once-daily therapy with completed Phase 3 trial meeting its primary endpoint.

• MNPR-101 is a Phase 1 radiopharmaceutical targeting uPAR in aggressive cancers.

• Leadership includes executives with successful drug development and commercialization backgrounds.

• Recent clinical data presented at major medical conferences; NDA filing for ALXN1840 targeted for 1H 2026.

ALXN1840 for Wilson disease: clinical and mechanistic data

• ALXN1840 met its Phase 3 primary endpoint, showing superior copper mobilization versus standard of care.

• Phase 2 trials demonstrated significant reduction in copper absorption and accumulation in liver and brain.

• Long-term data show sustained clinical improvement and favorable safety profile over six years.

• ALXN1840 offers once-daily dosing and may have a better or comparable risk profile to current therapies.

• Preclinical studies confirm decreased total body copper and safe transit through albumin processing sites.

Safety and tolerability

• Serious adverse events related to ALXN1840 were low, with no deaths and minimal renal or psychiatric events.

• No significant impact on kidney function observed over six years of treatment.

• Clean safety profile at sites of albumin processing, with low rates of adverse events in clinical trials.